Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attenuated Schedule Dara-RVd Induction for NDMM
NCT06348147Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jul 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, lenalidomide, bortezomib, dexamethasone in multiple myeloma (MM), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Jul 2026; status: withdrawn.
02
Drugs
daratumumablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06348147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348147.